Refine by
Clinical Data Articles & Analysis: Older
570 news found
Hemostemix Inc. (“Hemostemix” or the “Company”) (TSXV: HEM, OTCQB: HMTXF; FSE:2VF0), the leading autologous (patient’s own) stem cell therapy company treating no-option patients in Florida suffering in pain from Chronic Limb Threatening Ischemia, Peripheral Arterial Disease and Angina, is pleased to announce its webinar topic for Thursday, August 21, 2025. Croom ...
The ANDA contains information used for the review and approval of a generic drug product, and does not typically require preclinical and clinical trial data, but rather requires the inclusion of information on bioequivalence to the RLD. ...
SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a leader in data-driven medicine, will unveil new research at the European Society for Medical Oncology (ESMO) 2024. ...
Together, SOPHiA GENETICS and Boundless Bio pioneered the ecDNA Solution (ECS) algorithm to detect the presence of ecDNA using routine clinical next-generation sequencing (NGS) data. ECS is the first ecDNA clinical trial assay and was designed by SOPHiA GENETICS in alignment with FDA guidelines as an Investigational Use Only ...
As the volume and utility of data grows, SOPHiA GENETICS continues to accelerate innovation in the field of data-driven medicine by unveiling best-in-class technology and data science capabilities. ...
CanaQuest Medical Corp (“CanaQuest” or the “Company”) (OTC: CANQF), is pleased to announce strategic additions to its executive team with expertise in conducting clinical trials and US FDA drug approval success. The team plans to effectively navigate the regulatory approval process for Drug Candidate, CQ-001 (cannabidiol + proprietary API composition), to treat rare ...
In September 2023, Tempus and AstraZeneca initiated a pilot program to leverage Next to identify this specific care gap at participating provider sites, using AI to scan unstructured clinical data to understand which patients may be eligible for testing based on clinical guidelines, and notifying treating physicians to inform care. ...
ByTempus
Introduction Intraoperative irrigation is a commonly used method aimed at reducing microbial burden by removing tissue debris, metabolic waste, and tissue exudate from the surgical field prior to site closure.1 With the absence of universally established standard of care and robust clinical data, the selection of appropriate irrigation solution remains a ...
Caresyntax, the leading vendor of enterprise-scale data-driven surgical intelligence solutions to make surgery safer and smarter, today announced its highlights and achievements of 2023, as the company has continued its strong growth journey. Dennis Kogan, co-founder, and CEO: “Caresyntax celebrated its 10-year anniversary in 2023 and accelerated our journey of innovation ...
Caresyntax, the leading vendor-neutral surgical data and intelligence platform converging AI-powered software, devices, and clinical services, today announced the launch of Caresyntax Clinical Data as a Service (CDaaS) for Medtech industry partners. ...
The collaboration will leverage a secure infrastructure that is compliant with data privacy, information security, and regulatory concerns across the geographies. ...
Caresyntax, the leading vendor-neutral enterprise surgical data and intelligence platform designed to make surgery smarter and safer by converging AI-powered software, devices, and clinical services, today announced a partnership with ARC (Accelerate, Redesign, Collaborate) Sheba’s Global Innovation platform to establish and replicate the ARC Surgical ...
With more than 60 years’ expertise in respiratory diagnostics, Vitalograph is the only company in the world specialized in delivering clinical trial services exclusively for pulmonary function-focused studies. ...
Noninvasive flushing with the ReFlow Mini Flusher can be performed in-clinic by trained clinical staff, or anywhere by a trained patient/caregiver, as directed by the neurosurgeon. ...
Data from pivotal PHOTON trial demonstrate long term efficacy of aflibercept 8 mg with extended intervals comparable to Eylea (aflibercept 2 mg) at fixed 8-weekly dosing over two years Patients assigned to a 16-week dosing regimen at baseline received a mean of 7.8 injections (6 fewer than Eylea) Safety profile of aflibercept 8 mg in diabetic macular edema (DME) remains ...
ByBayer AG
The Neeka team has completed extensive due diligence on our science, preclinical data package, and our proprietary formulations prior to selecting CanaQuest as their cannabinoid partner for clinical studies and we are looking forward to a long-standing relationship and continuing to put science at the forefront of our company,” said Paul Ramsay, President ...
New Subgroup and further analyses from PULSAR, PHOTON and CANDELA provide insights into durability results of extended treatment intervals, patient characteristics as well as efficacy and safety of intravitreal aflibercept 8 mg In total, 18 presentations on aflibercept 8 mg and Eylea (aflibercept 2 mg) reinforce Bayer’s commitment to advancing treatment of patients with exudative retinal ...
ByBayer AG
Daxor Corporation (NYSE: DXR), the global leader in blood volume measurement technology, today announces new data validating the benefits of the Company’s BVA-100 diagnostic in optimizing individualized therapy for heart failure patients. Data were presented at the Technology Heart Failure Therapeutics Conference, which focuses on device and ...
The HFSA Optimal Medical Therapy in Heart Failure (OMT-HF) program can help your patients achieve their best outcomes. An estimated 6.5 million Americans have heart failure (HF). This year alone another 960,000 will likely be diagnosed with this condition. Chances are several of your patients are in this group. Are they receiving the optimal medical therapy (OMT), that helps them achieve ...
All-cause mortality was also reduced; no differences were observed between groups for the composite net-clinical benefit. The final data from this study were presented at the American Congress of Cardiology’s 72nd Annual Scientific Session together with World Congress of Cardiology (ACC.23/WCC). First data from XARENO that revealed the ...
ByBayer AG